Crossmark

Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature

Crossref DOI link: https://doi.org/10.1007/s00296-026-06168-3

Published Online: 2026-06-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sebastian, Agata

Kosałka-Węgiel, Joanna

Puchala, Mateusz https://orcid.org/0000-0002-0892-1870
Życińska, Katarzyna https://orcid.org/0000-0001-8496-6846
Kolarz, Bogdan

Bieniasz-Pawlik, Edyta

Korkosz, Mariusz https://orcid.org/0000-0002-1749-9739
License Information

Text and Data Mining valid from 2026-06-17

Version of Record valid from 2026-06-17
More Information

Article History

Received: 22 April 2026

Accepted: 27 May 2026

First Online: 17 June 2026

Declarations

Conflict of interest: The authors declare no conflicts of interest for this study.

Ethical approval: The study was conducted in accordance with the Declaration of Helsinki (December 2024 version) and was approved by the Ethics Committee of the Jagiellonian University Medical College (No. 1072.6120.2.17.2026; date of approval 12.01.2026).

Informed consent: Each participant involved in the study provided an informed consent.

Document is current

Any future updates will be listed below